69123
document
Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion : twelve-month results of a prospective , randomized , multicenter trial . PURPOSE This is a prospective , randomized , multicenter , investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution ( IH ) with prompt versus deferred intravitreal injections ( IVI ) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion ( CRVO ) . METHODS Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH ( group I , n = 28 ) or IH alone ( group II , n = 30 ) . From month 2 to 12 , the patients in both groups could be treated with monthly intravitreal ranibizumab . The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography . RESULTS At 12 months , eyes in group I on average gained +28.1 ( ±19.3 ) letters compared to +25.2 ( ±20.9 ) letters in group II ( p = 0.326 ) . This result was achieved with significantly fewer injections in group II . Additionally , 30 % of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial . CONCLUSION Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO . Initial IH in early CRVO may be a first treatment option in patients anxious about IVI .
69124
Intervention_Pharmacological
ranibizumab
69125
Intervention_Pharmacological
isovolemic hemodilution
69126
Intervention_Pharmacological
isovolemic hemodilution ( IH )
69127
Intervention_Pharmacological
ranibizumab 0.5 mg
69128
Intervention_Pharmacological
ranibizumab IVI
69129
Intervention_Pharmacological
IH
69130
Intervention_Pharmacological
IH
69131
Intervention_Pharmacological
ranibizumab .
69132
Outcome_Physical
gain of visual acuity and the course of central retinal thickness
69133
Outcome_Other
( ±19.3 ) letters
69134
Outcome_Physical
be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO
69135
Participant_Condition
Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously
69136
Participant_Condition
reducing macular edema secondary to CRVO